UNITED STATES SECURITIES AND EXCHANGE COMMISSION March 6, 2009

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Cadence Pharmaceuticals, Inc.

File No. 1-33103 - CF#22948

Cadence Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 8-K filed on December 5, 2008.

Based on representations by Cadence Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.1 through December 31, 2016 Exhibit 10.2 through December 5, 2018

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Karen J. Garnett Assistant Director